The lowering of the price target from $210 to $205 by Wedbush suggests a slightly bearish sentiment towards Biogen's stock. Maintaining a Neutral rating indicates no strong buy or sell recommendation, but the reduced target price may lead to a short-term negative impact on the stock price.